BTOG 2021 | Recent trials of KRAS targeting and the future

Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, comments on recent trials for lung cancer treatment, highlighting investigation of G12C inhibitors for KRAS-mutant lung cancer and the possibility of G12C inhibitors being used in combination with immune checkpoint inhibitors in the future. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.